25.68 USD
-0.16 (-0.62%)
25.68 USD
0 (0%)
PGNY gets a fundamental rating of 7 out of 10. The analysis compared the fundamentals against 101 industry peers in the Health Care Providers & Services industry. PGNY scores excellent points on both the profitability and health parts. This is a solid base for a good stock. PGNY is growing strongly while it is still valued neutral. This is a good combination! These ratings would make PGNY suitable for growth and quality investing!
1. Profitability
1.1 Basic Checks
In the past year PGNY was profitable.
In the past year PGNY had a positive cash flow from operations.
Each year in the past 5 years PGNY has been profitable.
In the past 5 years PGNY always reported a positive cash flow from operatings.
1.2 Ratios
Looking at the Return On Assets, with a value of 7.11%, PGNY belongs to the top of the industry, outperforming 88.12% of the companies in the same industry.
Looking at the Return On Equity, with a value of 10.10%, PGNY is in the better half of the industry, outperforming 71.29% of the companies in the same industry.
PGNY has a Return On Invested Capital of 11.24%. This is amongst the best in the industry. PGNY outperforms 83.17% of its industry peers.
PGNY had an Average Return On Invested Capital over the past 3 years of 8.25%. This is in line with the industry average of 9.58%.
The 3 year average ROIC (8.25%) for PGNY is below the current ROIC(11.24%), indicating increased profibility in the last year.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.11% | ||
| ROE | 10.1% | ||
| ROIC | 11.24% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
1.3 Margins
PGNY's Profit Margin of 4.46% is fine compared to the rest of the industry. PGNY outperforms 77.23% of its industry peers.
PGNY's Profit Margin has declined in the last couple of years.
PGNY has a Operating Margin of 6.77%. This is in the better half of the industry: PGNY outperforms 69.31% of its industry peers.
PGNY's Operating Margin has improved in the last couple of years.
Looking at the Gross Margin, with a value of 22.94%, PGNY is in line with its industry, outperforming 48.51% of the companies in the same industry.
In the last couple of years the Gross Margin of PGNY has grown nicely.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| OM | 6.77% | ||
| PM (TTM) | 4.46% | ||
| GM | 22.94% |
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
2. Health
2.1 Basic Checks
The Return on Invested Capital (ROIC) is just above the Cost of Capital (WACC), so PGNY is still creating some value.
PGNY has less shares outstanding than it did 1 year ago.
Compared to 5 years ago, PGNY has more shares outstanding
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
2.2 Solvency
PGNY has an Altman-Z score of 8.55. This indicates that PGNY is financially healthy and has little risk of bankruptcy at the moment.
PGNY has a better Altman-Z score (8.55) than 93.07% of its industry peers.
There is no outstanding debt for PGNY. This means it has a Debt/Equity and Debt/FCF ratio of 0 and it is amongst the best of the sector and industry.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Altman-Z | 8.55 |
ROIC/WACC1.26
WACC8.95%
2.3 Liquidity
PGNY has a Current Ratio of 2.96. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
The Current ratio of PGNY (2.96) is better than 84.16% of its industry peers.
PGNY has a Quick Ratio of 2.96. This indicates that PGNY is financially healthy and has no problem in meeting its short term obligations.
PGNY's Quick ratio of 2.96 is amongst the best of the industry. PGNY outperforms 84.16% of its industry peers.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Current Ratio | 2.96 | ||
| Quick Ratio | 2.96 |
3. Growth
3.1 Past
The Earnings Per Share has grown by an nice 8.62% over the past year.
The Earnings Per Share has been decreasing by -4.77% on average over the past years.
Looking at the last year, PGNY shows a quite strong growth in Revenue. The Revenue has grown by 11.41% in the last year.
Measured over the past years, PGNY shows a very strong growth in Revenue. The Revenue has been growing by 38.42% on average per year.
EPS 1Y (TTM)8.62%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%36.36%
Revenue 1Y (TTM)11.41%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.32%
3.2 Future
The Earnings Per Share is expected to grow by 32.94% on average over the next years. This is a very strong growth
Based on estimates for the next years, PGNY will show a quite strong growth in Revenue. The Revenue will grow by 8.83% on average per year.
EPS Next Y17.75%
EPS Next 2Y38.5%
EPS Next 3Y32.43%
EPS Next 5Y32.94%
Revenue Next Year11.28%
Revenue Next 2Y10.4%
Revenue Next 3Y10.6%
Revenue Next 5Y8.83%
3.3 Evolution
The EPS growth rate is accelerating: in the next years the growth will be better than in the last years.
The Revenue growth rate is decreasing: in the next years the growth will be less than in the last years.
4. Valuation
4.1 Price/Earnings Ratio
A Price/Earnings ratio of 40.76 indicates a quite expensive valuation of PGNY.
The rest of the industry has a similar Price/Earnings ratio as PGNY.
PGNY's Price/Earnings ratio indicates a rather expensive valuation when compared to the S&P500 average which is at 26.51.
The Price/Forward Earnings ratio is 23.49, which indicates a rather expensive current valuation of PGNY.
Compared to the rest of the industry, the Price/Forward Earnings ratio of PGNY is on the same level as its industry peers.
Compared to an average S&P500 Price/Forward Earnings ratio of 23.13, PGNY is valued at the same level.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.76 | ||
| Fwd PE | 23.49 |
4.2 Price Multiples
PGNY's Enterprise Value to EBITDA is on the same level as the industry average.
82.18% of the companies in the same industry are more expensive than PGNY, based on the Price/Free Cash Flow ratio.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| P/FCF | 11.44 | ||
| EV/EBITDA | 18.36 |
4.3 Compensation for Growth
The high PEG Ratio(NY), which compensates the Price/Earnings for growth, indicates PGNY does not grow enough to justify the current Price/Earnings ratio.
The decent profitability rating of PGNY may justify a higher PE ratio.
A more expensive valuation may be justified as PGNY's earnings are expected to grow with 32.43% in the coming years.
PEG (NY)2.3
PEG (5Y)N/A
EPS Next 2Y38.5%
EPS Next 3Y32.43%
5. Dividend
5.1 Amount
PGNY does not give a dividend.
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
25.68
-0.16 (-0.62%)
Chartmill FA Rating
GICS SectorHealth Care
GICS IndustryGroupHealth Care Equipment & Services
GICS IndustryHealth Care Providers & Services
Earnings (Last)
Earnings (Next)
Inst Owners104.97%
Inst Owner Change7.39%
Ins Owners1.49%
Ins Owner Change0.8%
Market Cap2.21B
Revenue(TTM)1.27B
Net Income(TTM)56.57M
Analysts81.25
Price Target29.68 (15.58%)
Short Float %7.13%
Short Ratio3.53
Dividend
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Dividend Yield | 0% |
Yearly DividendN/A
Dividend Growth(5Y)N/A
DPN/A
Div Incr Years0
Div Non Decr Years0
Ex-DateN/A
Surprises & Revisions
EPS beat(2)2
Avg EPS beat(2)14.43%
Min EPS beat(2)14.22%
Max EPS beat(2)14.63%
EPS beat(4)3
Avg EPS beat(4)8.02%
Min EPS beat(4)-11.77%
Max EPS beat(4)15%
EPS beat(8)5
Avg EPS beat(8)7.07%
EPS beat(12)9
Avg EPS beat(12)35.08%
EPS beat(16)13
Avg EPS beat(16)94.29%
Revenue beat(2)2
Avg Revenue beat(2)2.31%
Min Revenue beat(2)1.96%
Max Revenue beat(2)2.66%
Revenue beat(4)4
Avg Revenue beat(4)3.39%
Min Revenue beat(4)1.96%
Max Revenue beat(4)5.74%
Revenue beat(8)4
Avg Revenue beat(8)-0.43%
Revenue beat(12)7
Avg Revenue beat(12)0.39%
Revenue beat(16)9
Avg Revenue beat(16)-0.09%
PT rev (1m)1.12%
PT rev (3m)1.34%
EPS NQ rev (1m)0.39%
EPS NQ rev (3m)5.45%
EPS NY rev (1m)6.34%
EPS NY rev (3m)6.34%
Revenue NQ rev (1m)0%
Revenue NQ rev (3m)1.13%
Revenue NY rev (1m)1.4%
Revenue NY rev (3m)1.4%
Valuation
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| PE | 40.76 | ||
| Fwd PE | 23.49 | ||
| P/S | 1.75 | ||
| P/FCF | 11.44 | ||
| P/OCF | 10.64 | ||
| P/B | 3.95 | ||
| P/tB | 4.15 | ||
| EV/EBITDA | 18.36 |
EPS(TTM)0.63
EY2.45%
EPS(NY)1.09
Fwd EY4.26%
FCF(TTM)2.24
FCFY8.74%
OCF(TTM)2.41
OCFY9.4%
SpS14.72
BVpS6.5
TBVpS6.19
PEG (NY)2.3
PEG (5Y)N/A
Graham Number9.6
Profitability
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| ROA | 7.11% | ||
| ROE | 10.1% | ||
| ROCE | 14.68% | ||
| ROIC | 11.24% | ||
| ROICexc | 27.43% | ||
| ROICexgc | 30.82% | ||
| OM | 6.77% | ||
| PM (TTM) | 4.46% | ||
| GM | 22.94% | ||
| FCFM | 15.25% |
ROA(3y)7.58%
ROA(5y)11.89%
ROE(3y)10.72%
ROE(5y)17.23%
ROIC(3y)8.25%
ROIC(5y)7.66%
ROICexc(3y)19.18%
ROICexc(5y)17.15%
ROICexgc(3y)20.6%
ROICexgc(5y)18.86%
ROCE(3y)10.79%
ROCE(5y)10.01%
ROICexgc growth 3Y11.16%
ROICexgc growth 5Y-10.91%
ROICexc growth 3Y11.54%
ROICexc growth 5Y-2.19%
OM growth 3Y-3.61%
OM growth 5Y1.87%
PM growth 3Y-29.25%
PM growth 5YN/A
GM growth 3Y-1.03%
GM growth 5Y1.85%
F-Score7
Asset Turnover1.6
Health
| Industry Rank | Sector Rank | ||
|---|---|---|---|
| Debt/Equity | 0 | ||
| Debt/FCF | 0 | ||
| Debt/EBITDA | 0 | ||
| Cap/Depr | 330.21% | ||
| Cap/Sales | 1.16% | ||
| Interest Coverage | 250 | ||
| Cash Conversion | 230.54% | ||
| Profit Quality | 342.01% | ||
| Current Ratio | 2.96 | ||
| Quick Ratio | 2.96 | ||
| Altman-Z | 8.55 |
F-Score7
WACC8.95%
ROIC/WACC1.26
Cap/Depr(3y)177.5%
Cap/Depr(5y)150.16%
Cap/Sales(3y)0.4%
Cap/Sales(5y)0.39%
Profit Quality(3y)290.66%
Profit Quality(5y)196.79%
High Growth Momentum
Growth
EPS 1Y (TTM)8.62%
EPS 3Y-4.77%
EPS 5YN/A
EPS Q2Q%36.36%
EPS Next Y17.75%
EPS Next 2Y38.5%
EPS Next 3Y32.43%
EPS Next 5Y32.94%
Revenue 1Y (TTM)11.41%
Revenue growth 3Y32.6%
Revenue growth 5Y38.42%
Sales Q2Q%9.32%
Revenue Next Year11.28%
Revenue Next 2Y10.4%
Revenue Next 3Y10.6%
Revenue Next 5Y8.83%
EBIT growth 1Y31.12%
EBIT growth 3Y27.82%
EBIT growth 5Y41.01%
EBIT Next Year39.66%
EBIT Next 3Y20.34%
EBIT Next 5Y15.66%
FCF growth 1Y-2.78%
FCF growth 3Y93.67%
FCF growth 5YN/A
OCF growth 1Y2.69%
OCF growth 3Y90.18%
OCF growth 5YN/A
PROGYNY INC / PGNY FAQ
What is the fundamental rating for PGNY stock?
ChartMill assigns a fundamental rating of 7 / 10 to PGNY.
Can you provide the valuation status for PROGYNY INC?
ChartMill assigns a valuation rating of 4 / 10 to PROGYNY INC (PGNY). This can be considered as Fairly Valued.
How profitable is PROGYNY INC (PGNY) stock?
PROGYNY INC (PGNY) has a profitability rating of 7 / 10.
What is the earnings growth outlook for PROGYNY INC?
The Earnings per Share (EPS) of PROGYNY INC (PGNY) is expected to grow by 17.75% in the next year.